Literature DB >> 12323106

Oral lichen planus: clinical presentation and management.

Paul C Edwards1, Robert Kelsch.   

Abstract

Oral lichen planus (OLP) is a chronic mucosal condition commonly encountered in clinical dental practice. Lichen planus is believed to represent an abnormal immune response in which epithelial cells are recognized as foreign, secondary to changes in the antigenicity of the cell surface. It has various oral manifestations, the reticular form being the most common. The erosive and atrophic forms of OLP are less common, yet are most likely to cause symptoms. Topical corticosteroids constitute the mainstay of treatment for symptomatic lesions of OLP. Recalcitrant lesions can be treated with systemic steroids or other systemic medications. However, there is only weak evidence that these treatments are superior to placebo. Given reports of a slightly greater risk of squamous cell carcinoma developing in areas of erosive OLP, it is important for clinicians to maintain a high index of suspicion for all intraoral lichenoid lesions. Periodic follow-up of all patients with OLP is recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12323106

Source DB:  PubMed          Journal:  J Can Dent Assoc        ISSN: 0709-8936            Impact factor:   1.316


  45 in total

1.  Detection of T cells secreting type 1 and type 2 cytokines in the peripheral blood of patients with oral lichen planus.

Authors:  F Kalogerakou; E Albanidou-Farmaki; A K Markopoulos; D Z Antoniades
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

2.  Lipid profile and metabolic syndrome status in patients with oral lichen planus, oral lichenoid reaction and healthy individuals attending a dental college in northern India - a descriptive study.

Authors:  Bhuvana Krishnamoorthy; Suma Gn; Mamatha N S; Sowbhagya M B; Komali Garlapati
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 3.  Dental implants in patients affected by systemic diseases.

Authors:  N Donos; E Calciolari
Journal:  Br Dent J       Date:  2014-10       Impact factor: 1.626

4.  A comparative study of toluidine blue-mediated photodynamic therapy versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus: a randomized clinical controlled trial.

Authors:  Hasan Hoseinpour Jajarm; Farnaz Falaki; Majid Sanatkhani; Meysam Ahmadzadeh; Farzaneh Ahrari; Hooman Shafaee
Journal:  Lasers Med Sci       Date:  2014-12-09       Impact factor: 3.161

Review 5.  Neoplastic transformation of oral lichen: case report and review of the literature.

Authors:  G Abbate; A M Foscolo; M Gallotti; A Lancella; F Mingo
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-02       Impact factor: 2.124

6.  Oral lichen planus: A retrospective study of 110 Brazilian patients.

Authors:  Mônica Ghislaine Oliveira Alves; Janete Dias Almeida; Ivan Balducci; Luiz Antonio Guimarães Cabral
Journal:  BMC Res Notes       Date:  2010-06-03

7.  Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus.

Authors:  Josip Lukac; Suzana Brozović; Vanja Vucicević-Boras; Marinka Mravak-Stipetić; Branko Malenica; Zvonko Kusić
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

8.  Oral lichen planus treated with tacrolimus 0.1%.

Authors:  João Paulo Marinho Resende; Maria das Graças Afonso Miranda Chaves; Fernando Monteiro Aarestrup; Beatriz Vieira Aarestrup; Sergio Olate; Henrique Duque Netto
Journal:  Int J Clin Exp Med       Date:  2013-10-25

Review 9.  Black pepper and its bioactive constituent piperine: promising therapeutic strategies for oral lichen planus.

Authors:  Jing-Ya Yang; Jing Zhang; Gang Zhou
Journal:  Inflammopharmacology       Date:  2018-10-20       Impact factor: 4.473

10.  Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.

Authors:  Manuelle Viguier; Hervé Bachelez; Béatrice Poirier; Jérémy Kagan; Maxime Battistella; François Aubin; Antoine Touzé; Maryvonnick Carmagnat; Camille Francès; Marie-Lise Gougeon; Nicolas Fazilleau
Journal:  J Invest Dermatol       Date:  2014-09-10       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.